Ex-Cedilla CEO Glucksmann explores ‘new frontier’ at Sensorium; R&D chief out at Merck women’s health spinoff Organon
Alexandra Glucksmann is always looking for “the next frontier” in medicine. After spending most of her career in genetic diseases, rare diseases and oncology, her next pursuit is in mental health.
The longtime biopharma executive is the next CEO at Sensorium Therapeutics, a biotech leveraging machine learning to develop new mental health treatments, starting from plant components that are known to be psychoactive. The company’s lead program in anxiety is currently in preclinical testing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.